Effects of CYP4F2 Polymorphism on Response to Warfarin During Induction Phase: A Prospective, Open-Label, Observational Cohort Study

被引:19
作者
Bejarano-Achache, Idit [1 ,2 ]
Levy, Liran [1 ]
Mlynarsky, Liat [1 ]
Bialer, Meir [2 ]
Muszkat, Mordechai [1 ]
Caraco, Yoseph [1 ]
机构
[1] Hadassah Univ Hosp, Div Med, Clin Pharmacol Unit, IL-91120 Jerusalem, Israel
[2] Hebrew Univ Jerusalem, Fac Med, Sch Pharm, Inst Drug Res, Jerusalem, Israel
基金
以色列科学基金会;
关键词
3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitors; CYP4F2; pharmacogenetics; statin; variability; warfarin; K EPOXIDE REDUCTASE; DOSE REQUIREMENTS; CLINICAL-OUTCOMES; GENETIC POLYMORPHISMS; ANTICOAGULANT-THERAPY; VKORC1; HAPLOTYPES; CYP2C9; GENOTYPE; ASSOCIATION; POPULATION; VARIABILITY;
D O I
10.1016/j.clinthera.2012.02.009
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: The cytochrome P450 (GYP) 4F2 isozyme has been reported to metabolize vitamin K-1 in vitro, and the V433M polymorphism in the CYP4F2 gene has been associated with reduced vitamin K1 metabolism and the need for a higher maintenance dosage in patients receiving warfarin. Objective: The purpose of the present study was to evaluate the effects of V433M polymorphism on warfarin response during the induction phase. Methods: Warfarin-naive white patients in whom warfarin was scheduled to be initiated with a target INR of 2 to 3 were enrolled into the study. On enrollment, a single blood sample for the genotyping of CYP4F2, CYP2C9, and VKORC1 was drawn. The international normalized ratio (INR) was followed daily during induction and twice weekly until stable anticoagulation was reached. The relationships between several markers of warfarin response during induction and CYP4F2 polymorphism were determined. Results: The cohort coasisted of 241 patients (115 men; mean [SD] age, 55.2 [19.4] years; weight, 79.5 [18.3] kg). Most of the patients were carriers of the CYP4F2 CC genotype (112 patients) or the CT genotype (104 patients). In carriers of the TT genotype (25 patients), INR >3 was >4-fold lower compared with that in carriers of the CC or CT genotype, suggesting that patients with the IT genotype were less sensitive to warfarin during induction. Also in TT carriers, the extent of excessive anticoagulation was >10-fold lower than in the other carriers. Both of these findings had a nominal P value of <0.05. After adjustment for false discovery rate, none of the findings remained significant at a threshold q value of <0.05. Among CC carriers, the concurrent use of a statin was associated with a 1-mg/d reduction in warfarin maintenance dosage. No similar effect was noted in the CT or TT carriers, suggesting a possible genetic influence on warfarin-statin interaction. Conclusions: These preliminary findings suggest that among white patients treated with warfarin, CYP4F2 polymorphism had a measurable effect on warfarin responsiveness during induction; however, the observed differences failed to reach the level of statistical significance. The possibility that the effect of statins on warfarin anticoagulation varies among carriers of different CYP4F2 genotypes could not be excluded and should be evaluated further in a larger patient sample. (Clin Ther. 2012;34:811-823) (C) 2012 Elsevier HS Journals, Inc. All rights reserved.
引用
收藏
页码:811 / 823
页数:13
相关论文
共 50 条
[1]   Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications [J].
Aithal, GP ;
Day, CP ;
Kesteven, PJL ;
Daly, AK .
LANCET, 1999, 353 (9154) :717-719
[2]   Pharmacology and management of the vitamin K antagonists [J].
Ansell, Jack ;
Hirsh, Jack ;
Hylek, Elaine ;
Jacobson, Alan ;
Crowther, Mark ;
Palareti, Gualtiero .
CHEST, 2008, 133 (06) :160S-198S
[3]   Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P4502C9 gene polymorphisms on warfarin dose requirements [J].
Aquilante, CL ;
Langaee, TY ;
Lopez, LM ;
Yarandi, HN ;
Tromberg, JS ;
Mohuczy, D ;
Gaston, KL ;
Waddell, CD ;
Chirico, MJ ;
Johnson, JA .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (04) :291-302
[4]   Controlling the false discovery rate in behavior genetics research [J].
Benjamini, Y ;
Drai, D ;
Elmer, G ;
Kafkafi, N ;
Golani, I .
BEHAVIOURAL BRAIN RESEARCH, 2001, 125 (1-2) :279-284
[5]   CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population [J].
Borgiani, P. ;
Ciccacci, C. ;
Forte, V. ;
Sirianni, E. ;
Novelli, L. ;
Bramanti, P. ;
Novelli, G. .
PHARMACOGENOMICS, 2009, 10 (02) :261-266
[6]   CYP4F2 genetic variant alters required warfarin dose [J].
Caldwell, Michael D. ;
Awad, Tarif ;
Johnson, Julie A. ;
Gage, Brian F. ;
Falkowski, Mat ;
Gardina, Paul ;
Hubbard, Jason ;
Turpaz, Yaron ;
Langaee, Taimour Y. ;
Eby, Charles ;
King, Cristi R. ;
Brower, Amy ;
Schmelzer, John R. ;
Glurich, Ingrid ;
Vidaillet, Humberto J. ;
Yale, Steven H. ;
Zhang, Kai Qi ;
Berg, Richard L. ;
Burmester, James K. .
BLOOD, 2008, 111 (08) :4106-4112
[7]   Evaluation of Genetic Factors for Warfarin Dose Prediction [J].
Caldwell, Michael D. ;
Berg, Richard L. ;
Zhang, Kai Qi ;
Glurich, Ingrid ;
Schmelzer, John R. ;
Yale, Steven H. ;
Vidaillet, Humberto J. ;
Burmester, James K. .
CLINICAL MEDICINE & RESEARCH, 2007, 5 (01) :8-16
[8]   CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation:: A prospective randomized controlled study [J].
Caraco, Y. ;
Blotnick, S. ;
Muszkat, M. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 (03) :460-470
[9]   Genetic and Clinical Predictors of Warfarin Dose Requirements in African Americans [J].
Cavallari, L. H. ;
Langaee, T. Y. ;
Momary, K. M. ;
Shapiro, N. L. ;
Nutescu, E. A. ;
Coty, W. A. ;
Viana, M. A. G. ;
Patel, S. R. ;
Johnson, J. A. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 (04) :459-464
[10]   Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis [J].
Chimowitz, MI ;
Lynn, MJ ;
Howlett-Smith, H ;
Stern, BJ ;
Hertzberg, VS ;
Frankel, MR ;
Levine, SR ;
Chaturvedi, S ;
Kasner, SE ;
Benesch, CG ;
Sila, CA ;
Jovin, TG ;
Romano, JG .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (13) :1305-1316